Marina M. Zafranskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marina M. Zafranskaya has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Darya B. Nizheharodava
Research Institute of Experimental and Clinical Medicine, Belarusian State Medical University, Dzerzhinsky Ave. 83, 220083, Minsk, Republic of Belarus
6 shared publications - Alexander S. Fedulov
Belаrusian State Medical University
3 shared publications - Elizaveta M. Nazaranka
Belarusian State Medical University
2 shared publications - Svetlana S. Bagatka
Research Institute of Experimental and Clinical Medicine, Belarusian State Medical University, Dzerzhinsky Ave. 83, 220083, Minsk, Republic of Belarus
2 shared publications A. D. Dubko
International Sakharov Environmental Institute of the Belarusian State University
1 shared publication- A. V. Borisov
Belаrusian State Medical University
1 shared publication
Latest Publications
- Open Access
- 21 October 2025
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 09 (04) , 1-23
Immunologic Response after COVID-19 Vaccination in Heart Transplant Recipients
To date, all large-scale randomized controlled trials for COVID-19 vaccines have excluded solid organ transplant recipients; therefore, the effectiveness and safety of COVID-19 vaccines in preventing coronavirus infection using COVID-19 vaccines in patients with heart transplants have not been sufficiently studied. This paper presents the characteristics of humoral and cellular immunity in heart transplant recipients following vaccination against coronavirus infection. The study group consisted of 40 patients who underwent orthotopic heart transplantation between 2019 and 2014. They were vaccinated twice with the Vero Cell vaccine (China) or received a 3-dose vaccination with Gam-COVID-Vac (Sputnik V, Russia) booster. 63% of vaccinated individuals with no previous COVID-19 history and 85% of patients with a history of COVID-19 were to develop humoral post-vaccination immunity. The humoral response in patients who seroconverted before vaccination showed high level of virus-specific IgG antibodies to SARS-CoV-2 S protein during the post-vaccination period, with a statistically increase observed 9-12 months after the booster. The specific cellular response to the SARS-CoV-2 S and N proteins remained low throughout the entire follow-up period, and was recorded in 5-40% of heart transplant recipients. A significantly increased number of S- and N-specific T cells was observed 4-6 months after the secondary immunization. Starting from 21-28 days after the primary vaccination and continuing for a year after the booster, increased plasmablasts (CD27highCD38high B cells) were observed, correlating with neutralizing and spike-specific antibodies. In heart transplant recipients, vaccination against coronavirus infection does not result in increased serum autoantibodies (RF-IgG and IgA-RF, anti-SSR, cardiolipin IgG, β2-glycoprotein IgG, ANA, ANCA-Pro, anti-SLA/LP, anti-GD-IgA). In our study, vaccinated heart transplant recipients with a history of coronavirus infection showed an increased level of anti-IFN-α antibodies for 9-12 months after the basic vaccination. This finding, when associated with HLA alleles, must be taken into account for identifying patients at a potential risk of a severe disease.
- 21 October 2025
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 09 (04) , 1-23
Open AccessImmunologic Response after COVID-19 Vaccination in Heart Transplant Recipients
To date, all large-scale randomized controlled trials for COVID-19 vaccines have excluded solid organ transplant recipients; therefore, the effectiveness and safety of COVID-19 vaccines in preventing coronavirus infection using COVID-19 vaccines in patients with heart transplants have not been sufficiently studied. This paper presents the characteristics of humoral and cellular immunity in heart transplant recipients following vaccination against coronavirus infection. The study group consisted of 40 patients who underwent orthotopic heart transplantation between 2019 and 2014. They were vaccinated twice with the Vero Cell vaccine (China) or received a 3-dose vaccination with Gam-COVID-Vac (Sputnik V, Russia) booster. 63% of vaccinated individuals with no previous COVID-19 history and 85% of patients with a history of COVID-19 were to develop humoral post-vaccination immunity. The humoral response in patients who seroconverted before vaccination showed high level of virus-specific IgG antibodies to SARS-CoV-2 S protein during the post-vaccination period, with a statistically increase observed 9-12 months after the booster. The specific cellular response to the SARS-CoV-2 S and N proteins remained low throughout the entire follow-up period, and was recorded in 5-40% of heart transplant recipients. A significantly increased number of S- and N-specific T cells was observed 4-6 months after the secondary immunization. Starting from 21-28 days after the primary vaccination and continuing for a year after the booster, increased plasmablasts (CD27highCD38high B cells) were observed, correlating with neutralizing and spike-specific antibodies. In heart transplant recipients, vaccination against coronavirus infection does not result in increased serum autoantibodies (RF-IgG and IgA-RF, anti-SSR, cardiolipin IgG, β2-glycoprotein IgG, ANA, ANCA-Pro, anti-SLA/LP, anti-GD-IgA). In our study, vaccinated heart transplant recipients with a history of coronavirus infection showed an increased level of anti-IFN-α antibodies for 9-12 months after the basic vaccination. This finding, when associated with HLA alleles, must be taken into account for identifying patients at a potential risk of a severe disease.
- Open Access
- 27 December 2024
- Published by International Sakharov Environmental Institute of Belarusian State University in Journal of the Belarusian State University. Ecology
- No. 4,p. 85-98
Tumor microenvironment: systematic review
The growth and progression of a neoplasm is a multi–stage process mediated by interactions between tumor cells and their surrounding stroma including various cell types (fibroblasts, endothelial cells, immune cells), cell-free components (cytokines, extracellular vesicles and extracellular matrix), blood and lymphatic vessels that form the tumor microenvironment. During the progression of neoplasms, tumor cells can evade the immune response by suppressing or losing tumor antigens releasing immunosuppressive extracellular vesicles and exosomes, secreting various cytokines, chemokines and other factors, and begin to reprogram and remodel the surrounding stroma. The most relevant areas of TME study are cells and molecules of innate and acquired immunity exhibited both suppressive and stimulating activity against tumor cells due to their high heterogeneity and plasticity. Special attention is paid to immune control points, tumor microbiota, components of intercellular interaction as well as immunotherapy of tumor diseases. In this paper, a systematic review of scientific publications in PubMed database devoted to the study of TME and published in the period from 2019 to 2024 was carried out. 2547 sources were studied and 68 articles were selected during the screening process. Search queries and keywords included «tumor microenvironment», «immune cells», «tumor», «oncogenesis», «metastasis». The formed group of scientific articles will allow to study in more detail the cellular and molecular composition of the tumor microenvironment, as well as the main targets for the development of new approaches for malignant neoplasms diagnosis and therapy involving TME.
- 27 December 2024
- Published by International Sakharov Environmental Institute of Belarusian State University in Journal of the Belarusian State University. Ecology
- No. 4,p. 85-98
Open AccessTumor microenvironment: systematic review
The growth and progression of a neoplasm is a multi–stage process mediated by interactions between tumor cells and their surrounding stroma including various cell types (fibroblasts, endothelial cells, immune cells), cell-free components (cytokines, extracellular vesicles and extracellular matrix), blood and lymphatic vessels that form the tumor microenvironment. During the progression of neoplasms, tumor cells can evade the immune response by suppressing or losing tumor antigens releasing immunosuppressive extracellular vesicles and exosomes, secreting various cytokines, chemokines and other factors, and begin to reprogram and remodel the surrounding stroma. The most relevant areas of TME study are cells and molecules of innate and acquired immunity exhibited both suppressive and stimulating activity against tumor cells due to their high heterogeneity and plasticity. Special attention is paid to immune control points, tumor microbiota, components of intercellular interaction as well as immunotherapy of tumor diseases. In this paper, a systematic review of scientific publications in PubMed database devoted to the study of TME and published in the period from 2019 to 2024 was carried out. 2547 sources were studied and 68 articles were selected during the screening process. Search queries and keywords included «tumor microenvironment», «immune cells», «tumor», «oncogenesis», «metastasis». The formed group of scientific articles will allow to study in more detail the cellular and molecular composition of the tumor microenvironment, as well as the main targets for the development of new approaches for malignant neoplasms diagnosis and therapy involving TME.
- Open Access
- 28 July 2024
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 14 (3) , 443-450
Characteristics of virus-specific immunological reactions following COVID-19 vaccination in heart transplant recipients
Heart transplant patients are at an increased risk of COVID-19 infection adverse outcomes because of underlying immunosuppression and concomitant comorbidities. To date, all large-scale randomized controlled trials for various COVID-19 vaccines have excluded solid organ transplant recipients. Therefore, the efficacy and safety of coronavirus infection prevention using COVID-19 vaccines in transplant heart patients has not been sufficiently studied. In this research, the evaluation of virus-specific immunological reactions after vaccination (double Vero Cell vaccination and Sputnik Light booster vaccination) in heart transplant patients has been carried out. In vaccinated heart transplant individuals who did not have a history of COVID-19, starting from 4–6 months after the 2nd dose of the vaccine, an increase in antibodies to S protein level of was observed, while maintaining statistically significant differences for 9–12 months after vaccination (regardless of whether with or without booster vaccination). However, the concentration of antibodies remained low, and 37% of patients detected no antibodies. In vaccinated heart transplant individuals following the previous COVID-19 infection, as compared to seronegative patients, post-vaccination immunity is accompanied by maintaining a high level of virus-specific IgG antibodies to the S protein of the SARS-CoV-2 virus in the dynamics of the post-vaccination period with a statistically significant increase of these antibodies by 9–12 months after booster vaccination. The specific cellular response (according to the assessment of CD3⁺154⁺ and CD3⁺IFNγ⁺ TNFα⁺ cells) to the S protein of the SARS-CoV-2 virus remained low throughout the entire follow-up period, was recorded in 5–40% of heart transplant patients and statistically significant changes in the number of spikereactive lymphocytes were observed in patients with a history of COVID-19 by 4–6 months after administration of the 2nd dose of the vaccine. This, together with the results of the assessment of the humoral response, indicates a more pronounced post-vaccination immunity in patients with a hybrid immunity. While developing a methodology for assessing the risk and benefit of a vaccination strategy for individual heart transplant patients, clinical efficacy, ongoing monitoring of rare serious adverse events, and data on vaccine immunogenicity should be taken into account.
- 28 July 2024
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 14 (3) , 443-450
Open AccessCharacteristics of virus-specific immunological reactions following COVID-19 vaccination in heart transplant recipients
Heart transplant patients are at an increased risk of COVID-19 infection adverse outcomes because of underlying immunosuppression and concomitant comorbidities. To date, all large-scale randomized controlled trials for various COVID-19 vaccines have excluded solid organ transplant recipients. Therefore, the efficacy and safety of coronavirus infection prevention using COVID-19 vaccines in transplant heart patients has not been sufficiently studied. In this research, the evaluation of virus-specific immunological reactions after vaccination (double Vero Cell vaccination and Sputnik Light booster vaccination) in heart transplant patients has been carried out. In vaccinated heart transplant individuals who did not have a history of COVID-19, starting from 4–6 months after the 2nd dose of the vaccine, an increase in antibodies to S protein level of was observed, while maintaining statistically significant differences for 9–12 months after vaccination (regardless of whether with or without booster vaccination). However, the concentration of antibodies remained low, and 37% of patients detected no antibodies. In vaccinated heart transplant individuals following the previous COVID-19 infection, as compared to seronegative patients, post-vaccination immunity is accompanied by maintaining a high level of virus-specific IgG antibodies to the S protein of the SARS-CoV-2 virus in the dynamics of the post-vaccination period with a statistically significant increase of these antibodies by 9–12 months after booster vaccination. The specific cellular response (according to the assessment of CD3⁺154⁺ and CD3⁺IFNγ⁺ TNFα⁺ cells) to the S protein of the SARS-CoV-2 virus remained low throughout the entire follow-up period, was recorded in 5–40% of heart transplant patients and statistically significant changes in the number of spikereactive lymphocytes were observed in patients with a history of COVID-19 by 4–6 months after administration of the 2nd dose of the vaccine. This, together with the results of the assessment of the humoral response, indicates a more pronounced post-vaccination immunity in patients with a hybrid immunity. While developing a methodology for assessing the risk and benefit of a vaccination strategy for individual heart transplant patients, clinical efficacy, ongoing monitoring of rare serious adverse events, and data on vaccine immunogenicity should be taken into account.
- Open Access
- 24 June 2024
- Published by International Sakharov Environmental Institute of Belarusian State University in Journal of the Belarusian State University. Ecology
- No. 2,p. 68-78
Immunopathogenesis and serological markers in Inflammatory Bowel Diseases
Inflammatory Bowel Diseases (IBDs), encompassing Crohn’s Disease (CD) and Ulcerative Colitis (UC), presents significant diagnostic and therapeutic challenges. The pathogenesis of IBDs, including CD and UC, involves the presence of pathogenic factors such as abnormal gut microbiota, immune response dysregulation, environmental changes, and gene variants. Although many investigations have tried to identify novel pathogenic factors associated with IBDs that are related to environmental, genetic, microbial, and immune response factors, a full understanding of IBDs pathogenesis is unclear. Cytokines have a crucial role in the pathogenesis of IBDs, where they control multiple aspects of the inflammatory response. The role of cytokines produced by innate and adaptive immune cells, as well as their relevance to the future therapy of IBDs are very important. Through a comprehensive analysis of the literature, we highlight the importance of antibodies such as Anti-Saccharomyces cerevisiae Antibodies (ASCA) and Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (pANCA) in distinguishing between CD and UC, predicting disease behavior, and guiding treatment decisions. Despite the progress, the need for markers with improved specificity and sensitivity is evident. This review explores immunopathogenesis and the role of serological markers in IBDs management, discusses current challenges, and anticipates future research directions. The review concludes with an optimistic outlook on the role of microbiota and cytokine in pathogenesis of IBDs, potential of novel biomarkers, personalized medicine, and the integration of advanced technologies to transform IBDs management.
- 24 June 2024
- Published by International Sakharov Environmental Institute of Belarusian State University in Journal of the Belarusian State University. Ecology
- No. 2,p. 68-78
Open AccessImmunopathogenesis and serological markers in Inflammatory Bowel Diseases
Inflammatory Bowel Diseases (IBDs), encompassing Crohn’s Disease (CD) and Ulcerative Colitis (UC), presents significant diagnostic and therapeutic challenges. The pathogenesis of IBDs, including CD and UC, involves the presence of pathogenic factors such as abnormal gut microbiota, immune response dysregulation, environmental changes, and gene variants. Although many investigations have tried to identify novel pathogenic factors associated with IBDs that are related to environmental, genetic, microbial, and immune response factors, a full understanding of IBDs pathogenesis is unclear. Cytokines have a crucial role in the pathogenesis of IBDs, where they control multiple aspects of the inflammatory response. The role of cytokines produced by innate and adaptive immune cells, as well as their relevance to the future therapy of IBDs are very important. Through a comprehensive analysis of the literature, we highlight the importance of antibodies such as Anti-Saccharomyces cerevisiae Antibodies (ASCA) and Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (pANCA) in distinguishing between CD and UC, predicting disease behavior, and guiding treatment decisions. Despite the progress, the need for markers with improved specificity and sensitivity is evident. This review explores immunopathogenesis and the role of serological markers in IBDs management, discusses current challenges, and anticipates future research directions. The review concludes with an optimistic outlook on the role of microbiota and cytokine in pathogenesis of IBDs, potential of novel biomarkers, personalized medicine, and the integration of advanced technologies to transform IBDs management.
- Open Access
- 2 December 2023
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 20 (4) , 299-307
Impact of the therapy that changes the clinical course of multiple sclerosis using allogeneic mesenchymal stem cell transplantation on the immunological parameters of patients
Рассеянный склероз (РС) – мультифакториальное аутоиммунное хроническое заболевание центральной нервной системы, проявляющееся многоочаговой неврологической симптоматикой и имеющее в типичных случаях на ранних стадиях ремиттирующее течение. РС является одной из важнейших проблем современной неврологии, что обусловлено значительной распространенностью заболевания, преобладанием в возрастной структуре пациентов от 20 до 40 лет, а также высокой инвалидизацией. Основной мишенью терапевтических опций при РС является воздействие на иммунную систему с целью подавления воспалительного процесса, который приводит к демиелинизации. При использовании препаратов, позволяющих модифицировать клиническое течение РС (бета-интерферон, глатирамера ацетат, финголимод и др.), у 40 % пациентов отмечается хороший эффект, у 40 % – сомнительный, у 20 % нет ответа на лечение. Отсутствие оптимальных протоколов лечения РС, направленных на селективное подавление аутореактивных клонов Т-лимфоцитов и восстановление поврежденных участков ЦНС, объясняет все возрастающий интерес исследователей к использованию иммуномодулирующих и нейропротекторных свойств мезенхимальных стволовых клеток (МСК). Относительные преимущества аллогенной трансплантации МСК по сравнению с аутологичной широко обсуждаются, однако не приводятся объективные доказательства превосходства одного вида клеточной терапии над другим. В связи с этим вопрос об использовании аутологичных или аллогенных культур при лечении РС остается спорным. Цель исследования ‒ изучить влияние болезнь-модифицирующей терапии с применением аллогенных мезенхимальных стромальных стволовых клеток на иммунологические показатели пациентов с РС. Оценена динамика ряда иммунологических биомаркеров 4 пациентов с рецидивно-ремиттирующим РС. Все пациенты мужчины. Медиана возраста – 35,0 ± 11,4 года. На период скрининга балл по шкале Expanded Disability Status Scale (EDSS) – 3,6 [2,5; 6,0]. Одновременно исследовали иммунологические и клеточно-морфологические показатели культур МСК, подготовленных из жировой ткани (ЖТ) 7 доноров. Из 7 образцов МСК ЖТ было выбрано 2 образца с наиболее высокими коэффициентами супрессии пролиферации Т-лимфоцитов, для которых было подобрано для терапии 4 биомедицинских клеточных продукта. У пациентов с РС через 6 мес. после трансплантации наблюдались наиболее значимые изменения ‒ уменьшение продукции γIFN, количества функционально незрелых «двойных позитивных» и «двойных негативных» Т-лимфоцитов и снижение цитотоксической направленности Т-лимфоцитов с γδТ-клеточным рецептором, характеризующейся увеличением количества клеток, экспрессирующих СD45RO+ (маркер клеток-памяти), в сочетании со снижением количества γδTCR CD314+ лимфоцитов (экспрессирующих ключевой активирующий киллерный рецептор). Предварительные результаты исследования о влиянии пересадки аллоМСК на иммунологический статус пациентов с РС позволяют предположить, что введение этих клеток может использоваться в качестве нового метода патогенетической, болезнь-модифицирующей терапии при данной патологии.
- 2 December 2023
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 20 (4) , 299-307
Open AccessImpact of the therapy that changes the clinical course of multiple sclerosis using allogeneic mesenchymal stem cell transplantation on the immunological parameters of patients
Рассеянный склероз (РС) – мультифакториальное аутоиммунное хроническое заболевание центральной нервной системы, проявляющееся многоочаговой неврологической симптоматикой и имеющее в типичных случаях на ранних стадиях ремиттирующее течение. РС является одной из важнейших проблем современной неврологии, что обусловлено значительной распространенностью заболевания, преобладанием в возрастной структуре пациентов от 20 до 40 лет, а также высокой инвалидизацией. Основной мишенью терапевтических опций при РС является воздействие на иммунную систему с целью подавления воспалительного процесса, который приводит к демиелинизации. При использовании препаратов, позволяющих модифицировать клиническое течение РС (бета-интерферон, глатирамера ацетат, финголимод и др.), у 40 % пациентов отмечается хороший эффект, у 40 % – сомнительный, у 20 % нет ответа на лечение. Отсутствие оптимальных протоколов лечения РС, направленных на селективное подавление аутореактивных клонов Т-лимфоцитов и восстановление поврежденных участков ЦНС, объясняет все возрастающий интерес исследователей к использованию иммуномодулирующих и нейропротекторных свойств мезенхимальных стволовых клеток (МСК). Относительные преимущества аллогенной трансплантации МСК по сравнению с аутологичной широко обсуждаются, однако не приводятся объективные доказательства превосходства одного вида клеточной терапии над другим. В связи с этим вопрос об использовании аутологичных или аллогенных культур при лечении РС остается спорным. Цель исследования ‒ изучить влияние болезнь-модифицирующей терапии с применением аллогенных мезенхимальных стромальных стволовых клеток на иммунологические показатели пациентов с РС. Оценена динамика ряда иммунологических биомаркеров 4 пациентов с рецидивно-ремиттирующим РС. Все пациенты мужчины. Медиана возраста – 35,0 ± 11,4 года. На период скрининга балл по шкале Expanded Disability Status Scale (EDSS) – 3,6 [2,5; 6,0]. Одновременно исследовали иммунологические и клеточно-морфологические показатели культур МСК, подготовленных из жировой ткани (ЖТ) 7 доноров. Из 7 образцов МСК ЖТ было выбрано 2 образца с наиболее высокими коэффициентами супрессии пролиферации Т-лимфоцитов, для которых было подобрано для терапии 4 биомедицинских клеточных продукта. У пациентов с РС через 6 мес. после трансплантации наблюдались наиболее значимые изменения ‒ уменьшение продукции γIFN, количества функционально незрелых «двойных позитивных» и «двойных негативных» Т-лимфоцитов и снижение цитотоксической направленности Т-лимфоцитов с γδТ-клеточным рецептором, характеризующейся увеличением количества клеток, экспрессирующих СD45RO+ (маркер клеток-памяти), в сочетании со снижением количества γδTCR CD314+ лимфоцитов (экспрессирующих ключевой активирующий киллерный рецептор). Предварительные результаты исследования о влиянии пересадки аллоМСК на иммунологический статус пациентов с РС позволяют предположить, что введение этих клеток может использоваться в качестве нового метода патогенетической, болезнь-модифицирующей терапии при данной патологии.
- Open Access
- 2 September 2021
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 65 (4) , 448-455-455
Engineering a whole rat liver scaffold
Engineering a three-dimensional scaffold opens up great prospects for creation of manufacturing biological artificial organs. The article presents a method of perfusion decellularization of a rat liver, with the main problems and options for their solution being analyzed. Perfusion of a donor liver with 0.1 % a sodium dodecyl sulfate (SDS) solution allows obtaining a high-quality cell-free matrix characterized by preserved hepatic architectonics, patent vascular bed, residual DNA of less than 1 %, no signs of collagen fibers destruction and tissue edema. The obtained scaffold can be used for recellularization by allogeneic cell cultures when creating volumetric tissue-engineered designs.
- 2 September 2021
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 65 (4) , 448-455-455
Open AccessEngineering a whole rat liver scaffold
Engineering a three-dimensional scaffold opens up great prospects for creation of manufacturing biological artificial organs. The article presents a method of perfusion decellularization of a rat liver, with the main problems and options for their solution being analyzed. Perfusion of a donor liver with 0.1 % a sodium dodecyl sulfate (SDS) solution allows obtaining a high-quality cell-free matrix characterized by preserved hepatic architectonics, patent vascular bed, residual DNA of less than 1 %, no signs of collagen fibers destruction and tissue edema. The obtained scaffold can be used for recellularization by allogeneic cell cultures when creating volumetric tissue-engineered designs.
- Open Access
- 11 November 2020
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 11, 380
Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period
Background: Treatment of patients with Parkinson disease (PD) using autologous mesenchymal stem cells (MSCs) is a promising method to influence the pathogenesis of the disease. The aim of this study was to assess the immediate results of the introduction of MSCs on the effectiveness of motor and nonmotor symptoms in patients with PD. Methods: MSCs were transplanted to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. Effectiveness of the therapy was evaluated 1 and 3 months posttransplantation. Neurological examination of the intensity of motor symptoms was carried out in the morning after a 12 or 24 h break in taking antiparkinsonian drugs, then 1 h after they were taken. The intensity of motor symptoms was assessed with the help of Section III of the Unified PD Rating Scale of the International Society for Movement Disorders (UPDRS). The intensity of nonmotor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, Nonmotor Symptoms Scale, and the 39-item Parkinson’s Disease Questionnaire. Results: We found a statistically significant decrease in the severity of motor and nonmotor symptoms in the study group in the posttransplant period. Conclusion: Positive results allow us to consider MSCs transplantation as a disease-modifying therapeutic strategy in PD. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period to monitor the patients’ condition posttransplantation.
- 11 November 2020
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 11, 380
Open AccessMesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period
Background: Treatment of patients with Parkinson disease (PD) using autologous mesenchymal stem cells (MSCs) is a promising method to influence the pathogenesis of the disease. The aim of this study was to assess the immediate results of the introduction of MSCs on the effectiveness of motor and nonmotor symptoms in patients with PD. Methods: MSCs were transplanted to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. Effectiveness of the therapy was evaluated 1 and 3 months posttransplantation. Neurological examination of the intensity of motor symptoms was carried out in the morning after a 12 or 24 h break in taking antiparkinsonian drugs, then 1 h after they were taken. The intensity of motor symptoms was assessed with the help of Section III of the Unified PD Rating Scale of the International Society for Movement Disorders (UPDRS). The intensity of nonmotor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, Nonmotor Symptoms Scale, and the 39-item Parkinson’s Disease Questionnaire. Results: We found a statistically significant decrease in the severity of motor and nonmotor symptoms in the study group in the posttransplant period. Conclusion: Positive results allow us to consider MSCs transplantation as a disease-modifying therapeutic strategy in PD. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period to monitor the patients’ condition posttransplantation.
- Open Access
- 30 June 2019
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 13 (2) , 32-40
The migration of multipotent mesenchymal stromal cells after systemic and local administration in an experimental model of Parkinson’s disease
Parkinson’s disease is an important medico-social problem worldwide, with a lot of attention paid to preclinical studies to assess the efficacy of new treatments, including cell therapy. Study objective. To assess the migratory ability of multipotent mesenchymal stromal cells (MMSC) using different methods of administration in an experimental model of Parkinson’s disease in laboratory rats. Materials and methods. MMSC, stained with the PKH26 fluorescent dye, were systemically (intravenously) or locally (intranasally and intrathecally) administered to experimental animals with rotenone-induced Parkinson’s disease. The migratory ability of MMSC was assessed on days 1 and 21 after administration, using immunofluorescence microscopy. Results. The migratory ability of MMSC after both systemic and local administration was more pronounced in the animal group with the experimental model of Parkinson’s disease compared with the control group. It was characterized by maximum accumulation of cells in the brain on the first day after administration, with viability preserved in the area of neuronal inflammation throughout 21 days. Conclusion. Local administration (intranasal and intrathecal) leads to faster accumulation of MMSC in the brain of both the animals with the experimental model of Parkinson’s disease and healthy rats. Intravenous administration of cell cultures also helps to reveal the migratory properties of MMSC and can form the basis for planning further studies of cell therapy in Parkinson’s disease.
- 30 June 2019
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 13 (2) , 32-40
Open AccessThe migration of multipotent mesenchymal stromal cells after systemic and local administration in an experimental model of Parkinson’s disease
Parkinson’s disease is an important medico-social problem worldwide, with a lot of attention paid to preclinical studies to assess the efficacy of new treatments, including cell therapy. Study objective. To assess the migratory ability of multipotent mesenchymal stromal cells (MMSC) using different methods of administration in an experimental model of Parkinson’s disease in laboratory rats. Materials and methods. MMSC, stained with the PKH26 fluorescent dye, were systemically (intravenously) or locally (intranasally and intrathecally) administered to experimental animals with rotenone-induced Parkinson’s disease. The migratory ability of MMSC was assessed on days 1 and 21 after administration, using immunofluorescence microscopy. Results. The migratory ability of MMSC after both systemic and local administration was more pronounced in the animal group with the experimental model of Parkinson’s disease compared with the control group. It was characterized by maximum accumulation of cells in the brain on the first day after administration, with viability preserved in the area of neuronal inflammation throughout 21 days. Conclusion. Local administration (intranasal and intrathecal) leads to faster accumulation of MMSC in the brain of both the animals with the experimental model of Parkinson’s disease and healthy rats. Intravenous administration of cell cultures also helps to reveal the migratory properties of MMSC and can form the basis for planning further studies of cell therapy in Parkinson’s disease.
- Open Access
- 14 August 2013
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 78 (5) , 455-462
PGE2 Contributes to In vitro MSC‐Mediated Inhibition of Non‐Specific and Antigen‐Specific T Cell Proliferation in MS Patients
Current theories of multiple sclerosis (MS) induction and progression place autoreactive T cells in the focus of the pathogenesis. Mesenchymal/stromal stem cells (MSC) have become a promising alternative approach for pathogenic therapy of MS due to their immunomodulatory properties, underlying mechanisms of which are intensive study. The objective of the research was to investigate the contribution of PGE2 to MSC-mediated suppression in patients with MS using in vitro model of mitogen- and myelin-stimulated T cell cocultivation with autologous/allogeneic MSC. We have showed that PGE2 production depends on cell-to-cell contact of MSC and lymphocytes. The antigenic stimulation did not affect PGE2 production following cocultivation of MSC and PBMC, and it is the presence of MSC in cell culture that significantly increases PGE2 production irrespective of antigenic cultivation conditions. Simultaneously, PGE2 synthesis correlated with indexes of MSC-mediated suppression of mitogen- and myelin-stimulated T cell proliferation in patients with MS. No significant differences in PGE2 production by autologous and allogeneic MSC have been established. These results have demonstrated that in patients with MS, PGE2 is one of the possible factors of MSC immunosuppression. The interrelation between PGE2 concentrations and T cell proliferation suppression mediated by MSC may explain one of the immune mechanisms of cell therapy, which is crucial for the further proper use of MSC in MS research and pathogenic treatment.
- 14 August 2013
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 78 (5) , 455-462
Open AccessPGE2 Contributes to In vitro MSC‐Mediated Inhibition of Non‐Specific and Antigen‐Specific T Cell Proliferation in MS Patients
Current theories of multiple sclerosis (MS) induction and progression place autoreactive T cells in the focus of the pathogenesis. Mesenchymal/stromal stem cells (MSC) have become a promising alternative approach for pathogenic therapy of MS due to their immunomodulatory properties, underlying mechanisms of which are intensive study. The objective of the research was to investigate the contribution of PGE2 to MSC-mediated suppression in patients with MS using in vitro model of mitogen- and myelin-stimulated T cell cocultivation with autologous/allogeneic MSC. We have showed that PGE2 production depends on cell-to-cell contact of MSC and lymphocytes. The antigenic stimulation did not affect PGE2 production following cocultivation of MSC and PBMC, and it is the presence of MSC in cell culture that significantly increases PGE2 production irrespective of antigenic cultivation conditions. Simultaneously, PGE2 synthesis correlated with indexes of MSC-mediated suppression of mitogen- and myelin-stimulated T cell proliferation in patients with MS. No significant differences in PGE2 production by autologous and allogeneic MSC have been established. These results have demonstrated that in patients with MS, PGE2 is one of the possible factors of MSC immunosuppression. The interrelation between PGE2 concentrations and T cell proliferation suppression mediated by MSC may explain one of the immune mechanisms of cell therapy, which is crucial for the further proper use of MSC in MS research and pathogenic treatment.